PLD2 and Hypertension: Placing all of these observations together, our findings reveal a novel pathway in which PLD2 deficiency decreases intracellular cholesterol, leading to increased HMG-CoA reductase protein expression and activity, which results in decreased eNOS expression, deceased production of the vasodilator NO, and, finally, hypertension (Fig. 6D).